SouthState’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
SouthState's LCTX Position: Q3 2026 in Review
SouthState opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 325 shares worth $311. The stake represents ﹤0.01% of the portfolio and ranks #1332 among its holdings.
109 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- SouthState held 325 shares of Lineage Cell Therapeutics worth $311 as of Q3 2026.
- Lineage Cell Therapeutics was a new SouthState position in Q3 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of SouthState's portfolio in Q3 2026, its #1332 holding.
- 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on SouthState's 13F filing for Q3 2026, filed 9 Nov 2026.